Ascendis to pay 20% Yuviwel royalties in patent settlement with BioMarin

In a deal that will end intellectual property claims in five countries, including one before the International Trade Commission, Ascendis has

lunedì 31 agosto 2026 New tab

702 words~3 min read

Fierce Pharma

Fierce Biotech

Fierce Healthcare

Fierce Life Sciences Events

Advertise

Other newsrooms on this story

· 3 sources

· 3 sources

BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S.,…

morningstar.com6 g fa

BioMarin Pharmaceutical and Ascendis Pharma settled global patent disputes over Yuviwel, granting BioMarin significant royalty…

benzinga.com6 g fa

With phase 3 results that have “exceeded” BioMarin’s expectations, according to R&D chief Greg Friberg, M.D., the California…

fiercepharma.com3 mesi fa

Four months after Theravance Biopharma shut down its R&D unit, laid | Four months after Theravance Biopharma shut down its R&D…

fiercepharma.com2 mesi fa

Ascendis pagará à BioMarin 20% das vendas líquidas do Yuviwel nos EUA, retroativos à primeira venda comercial, e de 18% das…

valor.globo.com6 g fa

As China-developed assets gain more attention from biopharma dealmakers, some industry watchers want to cur | As China-developed…

fiercepharma.com3 mesi fa